Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208510 | SCV000263945 | uncertain significance | Primary dilated cardiomyopathy | 2015-07-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002363042 | SCV002664322 | uncertain significance | Cardiovascular phenotype | 2021-11-19 | criteria provided, single submitter | clinical testing | The p.R231H variant (also known as c.692G>A), located in coding exon 6 of the GPD1L gene, results from a G to A substitution at nucleotide position 692. The arginine at codon 231 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV002517398 | SCV003445574 | uncertain significance | Brugada syndrome | 2022-08-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 231 of the GPD1L protein (p.Arg231His). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 222645). This variant has not been reported in the literature in individuals affected with GPD1L-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.003%). |